Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 2/2020

Open Access 01-02-2020 | Parkinson's Disease | Original Article

Abnormal pattern of brain glucose metabolism in Parkinson’s disease: replication in three European cohorts

Authors: Sanne K. Meles, Remco J. Renken, Marco Pagani, L. K. Teune, Dario Arnaldi, Silvia Morbelli, Flavio Nobili, Teus van Laar, Jose A. Obeso, Maria C. Rodríguez-Oroz, Klaus L. Leenders

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 2/2020

Login to get access

Abstract

Rationale

In Parkinson’s disease (PD), spatial covariance analysis of 18F-FDG PET data has consistently revealed a characteristic PD-related brain pattern (PDRP). By quantifying PDRP expression on a scan-by-scan basis, this technique allows objective assessment of disease activity in individual subjects. We provide a further validation of the PDRP by applying spatial covariance analysis to PD cohorts from the Netherlands (NL), Italy (IT), and Spain (SP).

Methods

The PDRPNL was previously identified (17 controls, 19 PD) and its expression was determined in 19 healthy controls and 20 PD patients from the Netherlands. The PDRPIT was identified in 20 controls and 20 “de-novo” PD patients from an Italian cohort. A further 24 controls and 18 “de-novo” Italian patients were used for validation. The PDRPSP was identified in 19 controls and 19 PD patients from a Spanish cohort with late-stage PD. Thirty Spanish PD patients were used for validation. Patterns of the three centers were visually compared and then cross-validated. Furthermore, PDRP expression was determined in 8 patients with multiple system atrophy.

Results

A PDRP could be identified in each cohort. Each PDRP was characterized by relative hypermetabolism in the thalamus, putamen/pallidum, pons, cerebellum, and motor cortex. These changes co-varied with variable degrees of hypometabolism in posterior parietal, occipital, and frontal cortices. Frontal hypometabolism was less pronounced in “de-novo” PD subjects (Italian cohort). Occipital hypometabolism was more pronounced in late-stage PD subjects (Spanish cohort). PDRPIT, PDRPNL, and PDRPSP were significantly expressed in PD patients compared with controls in validation cohorts from the same center (P < 0.0001), and maintained significance on cross-validation (P < 0.005). PDRP expression was absent in MSA.

Conclusion

The PDRP is a reproducible disease characteristic across PD populations and scanning platforms globally. Further study is needed to identify the topography of specific PD subtypes, and to identify and correct for center-specific effects.
Appendix
Available only for authorised users
Literature
1.
Palop JJ, Chin J, Mucke L. A network dysfunction perspective on neurodegenerative diseases. Nature. 2006;443:768–73.PubMed
2.
Reivich M, Kuhl D, Wolf A, Greenberg J, Phelps M, Ido T, et al. The [18F]fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res. 1979;44:127–37.PubMed
3.
Juh R, Kim J, Moon D, Choe B, Suh T. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET. Eur J Radiol. 2004;51:223–33.PubMed
4.
Eckert T, Barnes A, Dhawan V, Frucht S, Gordon MF, Feigin AS, et al. FDG PET in the differential diagnosis of parkinsonian disorders. Neuroimage. 2005;26:912–21.PubMed
5.
Teune LK, Bartels AL, de Jong BM, Willemsen AT, Eshuis SA, de Vries JJ, et al. Typical cerebral metabolic patterns in neurodegenerative brain diseases. Mov Disord. 2010;25:2395–404.PubMed
6.
Huang C, Ravdin LD, Nirenberg MJ, Piboolnurak P, Severt L, Maniscalco JS, et al. Neuroimaging markers of motor and nonmotor features of Parkinson’s disease: an 18f fluorodeoxyglucose positron emission computed tomography study. Dement Geriatr Cogn Disord. 2013;35:183–96.PubMed
7.
Wang R, Xu B, Guo Z, Chen T, Zhang J, Chen Y, et al. Suite PET/CT neuroimaging for the diagnosis of Parkinson’s disease: statistical parametric mapping analysis. Nucl Med Commun. 2017;38:164–9.PubMed
8.
Moeller JR, Strother SC, Sidtis JJ, Rottenberg DA. Scaled subprofile model: a statistical approach to the analysis of functional patterns in positron emission tomographic data. J Cereb Blood Flow Metab. 1987;7:649–58.PubMed
9.
Eidelberg D. Metabolic brain networks in neurodegenerative disorders: a functional imaging approach. Trends Neurosci. 2009;32:548–57.PubMedPubMedCentral
10.
Spetsieris PG, Eidelberg D. Scaled subprofile modeling of resting state imaging data in Parkinson's disease: methodological issues. Neuroimage. 2011;54:2899–914.PubMed
11.
Ma Y, Tang C, Spetsieris PG, Dhawan V, Eidelberg D. Abnormal metabolic network activity in Parkinson’s disease: test-retest reproducibility. J Cereb Blood Flow Metab. 2007;27:597–605.PubMed
12.
Schindlbeck KA, Eidelberg D. Network imaging biomarkers: insights and clinical applications in Parkinson’s disease. Lancet Neurol. 2018;17:629–40.PubMed
13.
Holtbernd F, Ma Y, Peng S, Schwartz F, Timmermann L, Kracht L, et al. Dopaminergic correlates of metabolic network activity in Parkinson’s disease. Hum Brain Mapp. 2015;36:3575–85.PubMedPubMedCentral
14.
Huang C, Tang C, Feigin A, Lesser M, Ma Y, Pourfar M, et al. Changes in network activity with the progression of Parkinson’s disease. Brain. 2007;130:1834–46.PubMed
15.
Niethammer M, Eidelberg D. Metabolic brain networks in translational neurology: concepts and Applications. Ann Neurol. 2012;72(5):635–47.PubMedPubMedCentral
16.
Asanuma K, Tang C, Ma Y, Dhawan V, Mattis P, Edwards C, et al. Network modulation in the treatment of Parkinson’s disease. Brain. 2006;129:2667–78.PubMed
17.
Holtbernd F, Gagnon JF, Postuma RB, Ma Y, Tang CC, Feigin A, et al. Abnormal metabolic network activity in REM sleep behavior disorder. Neurology. 2014;82:620–7.PubMedPubMedCentral
18.
Tang CC, Poston KL, Eckert T, Feigin A, Frucht S, Gudesblatt M, et al. Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol. 2010;9:149–58.PubMedPubMedCentral
19.
Tripathi M, Tang CC, Feigin A, De Lucia I, Nazem A, Dhawan V, et al. Automated differential diagnosis of early parkinsonism using metabolic brain networks: a validation study. J Nucl Med. 2016;57(1):60–6.PubMed
20.
Wu P, Wang J, Peng S, Ma Y, Zhang H, Guan Y, et al. Metabolic brain network in the Chinese patients with Parkinson’s disease based on 18F-FDG PET imaging. Parkinsonism Relat Disord. 2013;19:622–7.
21.
Tomse P, Jensterle L, Grmek M, Zaletel K, Pirtosek Z, Dhawan V, et al. Abnormal metabolic brain network associated with Parkinson’s disease: replication on a new European sample. Neuroradiology. 2017;59:507–15.PubMed
22.
Matthews DC, Lerman H, Lukic A, Andrews RD, Mirelman A, Wernick MN, et al. FDG PET Parkinson’s disease-related pattern as a biomarker for clinical trials in early stage disease. Neuroimage Clin. 2018;20:572–9.
23.
Teune LK, Renken RJ, Mudali D, De Jong BM, Dierckx RA, Roerdink JB, et al. Validation of parkinsonian disease-related metabolic brain patterns. Mov Disord. 2013;28:547–51.PubMed
24.
Teune LK, Renken RJ, de Jong BM, Willemsen AT, van Osch MJ, Roerdink JB, et al. Parkinson’s disease-related perfusion and glucose metabolic brain patterns identified with PCASL-MRI and FDG-PET imaging. Neuroimage Clin. 2014;5:240–4.
25.
Meles SK, Vadasz D, Renken RJ, Sittig-Wiegand E, Mayer G, Depboylu C, et al. FDG PET, dopamine transporter SPECT, and olfaction: combining biomarkers in REM sleep behavior disorder. Mov Disord. 2017;32:1482–6.PubMedPubMedCentral
26.
Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Mov Disord. 2015;30:1591–601.PubMed
27.
Arnaldi D, Morbelli S, Brugnolo A, Girtler N, Picco A, Ferrara M, et al. Functional neuroimaging and clinical features of drug naive patients with de novo Parkinson’s disease and probable RBD. Parkinsonism Relat Disord. 2016;29:47–53.
28.
Garcia-Garcia D, Clavero P, Gasca Salas C, Lamet I, Arbizu J, Gonzalez-Redondo R, et al. Posterior parietooccipital hypometabolism may differentiate mild cognitive impairment from dementia in Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2012;39:1767–77.PubMed
29.
Della Rosa PA, Cerami C, Gallivanone F, Prestia A, Caroli A, Castiglioni I, et al. A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics. 2014;12:575–93.PubMed
30.
Akaike H. A new look at the statistical model identification. IEEE Trans Autom Control. 1974;19(6):716–23.
31.
Habeck C, Foster NL, Perneczky R, Kurz A, Alexopoulos P, Koeppe RA, et al. Multivariate and univariate neuroimaging biomarkers of Alzheimer’s disease. Neuroimage. 2008;40:1503–15.PubMed
32.
Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, et al. The metabolic topography of parkinsonism. J Cereb Blood Flow Metab. 1994;14:783–801.
33.
Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, et al. Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. Lancet Neurol. 2009;8:1128–39.PubMed
34.
DeLong MR, Wichmann T. Circuits and circuit disorders of the basal ganglia. Arch Neurol. 2007;64:20–4.PubMed
35.
Su PC, Ma Y, Fukuda M, Mentis MJ, Tseng HM, Yen RF, et al. Metabolic changes following subthalamotomy for advanced Parkinson’s disease. Ann Neurol. 2001;50:514–20.PubMed
36.
Trost M, Su S, Su P, Yen RF, Tseng HM, Barnes A, et al. Network modulation by the subthalamic nucleus in the treatment of Parkinson’s disease. Neuroimage. 2006;31:301–7.PubMed
37.
Wang J, Ma Y, Huang Z, Sun B, Guan Y, Zuo C. Modulation of metabolic brain function by bilateral subthalamic nucleus stimulation in the treatment of Parkinson’s disease. J Neurol. 2010;257:72–8.PubMed
38.
Lin TP, Carbon M, Tang C, Mogilner AY, Sterio D, Beric A, et al. Metabolic correlates of subthalamic nucleus activity in Parkinson’s disease. Brain. 2008;131:1373–80.PubMed
39.
Berti V, Polito C, Ramat S, Vanzi E, De Cristofaro MT, Pellicano G, et al. Brain metabolic correlates of dopaminergic degeneration in de novo idiopathic Parkinson’s disease. Eur J Nucl Med Mol Imaging. 2010;37:537–44.PubMed
40.
Ko JH, Lerner RP, Eidelberg D. Effects of levodopa on regional cerebral metabolism and blood flow. Mov Disord. 2015;30:54–63.PubMed
41.
Gasca-Salas C, Clavero P, Garcia-Garcia D, Obeso JA, Rodriguez-Oroz MC. Significance of visual hallucinations and cerebral hypometabolism in the risk of dementia in Parkinson’s disease patients with mild cognitive impairment. Hum Brain Mapp. 2016;37:968–77.PubMed
42.
Hellwig S, Amtage F, Kreft A, Buchert R, Winz OH, Vach W, Spehl TS, Rijntjes M, Hellwig B, Weiller C, Winkler C, Weber WA, Tuscher O, Meyer PT. (1)(8)F]FDG-PET is superior to [(1)(2)(3)I]IBZM-SPECT for the differential diagnosis of parkinsonism. Neurology 2012;79:1314-22.PubMed
43.
Tripathi M, Dhawan V, Peng S, Kushwaha S, Batla A, Jaimini A, et al. Differential diagnosis of parkinsonian syndromes using F-18 fluorodeoxyglucose positron emission tomography. Neuroradiology. 2013;55:483–92.PubMed
44.
Brajkovic L, Kostic V, Sobic-Saranovic D, Stefanova E, Jecmenica-Lukic M, Jesic A, et al. The utility of FDG-PET in the differential diagnosis of parkinsonism. Neurol Res. 2017;39:675–84.PubMed
45.
Meyer PT, Frings L, Rucker G, Hellwig S. (18)F-FDG PET in parkinsonism: differential diagnosis and evaluation of cognitive impairment. J Nucl Med. 2017;58:1888–98.PubMed
46.
Meles SK, Teune LK, de Jong BM, Dierckx RA, Leenders KL. Metabolic imaging in parkinson disease. J Nucl Med. 2017;58:23–8.PubMed
47.
Ishibashi K, Onishi A, Fujiwara Y, Oda K, Ishiwata K, Ishii K. Longitudinal effects of aging on (18)F-FDG distribution in cognitively normal elderly individuals. Sci Rep. 2018;8(1):11557.
48.
Zhang N, Gordon ML, Ma Y, Chi B, Gomar JJ, Peng S, et al. The age-related perfusion pattern measured with arterial spin labeling MRI in healthy subjects. Front Aging Neurosci. 2018;10:214.
49.
Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Mandel F, Alexander GE, et al. The metabolic topography of normal aging. J Cereb Blood Flow Metab. 1996;16:385–98.
50.
Moeller JR, Eidelberg D. Divergent expression of regional metabolic topographies in Parkinson’s disease and normal ageing. Brain. 1997;120(Pt 12):2197–206.PubMed
51.
Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;86:566–76.PubMed
52.
Ko JH, Lee CS, Eidelberg D. Metabolic network expression in parkinsonism: clinical and dopaminergic correlations. J Cereb Blood Flow Metab. 2017;37(2):683–693.
53.
Tomse P, Jensterle L, Rep S, Grmek M, Zaletel K, Eidelberg D, et al. The effect of 18F-FDG-PET image reconstruction algorithms on the expression of characteristic metabolic brain network in Parkinson’s disease. Phys Med. 2017;41:129–35.PubMedPubMedCentral
54.
Tomse P, Peng S, Pirtosek Z, Zaletel K, Dhawan V, Eidelberg D, et al. The effects of image reconstruction algorithms on topographic characteristics, diagnostic performance and clinical correlation of metabolic brain networks in Parkinson’s disease. Phys Med. 2018;52:104–12.PubMed
55.
Kogan RV, de Jong BA, Renken RJ, Meles SK, van Snick PJH, Golla S, et al. Factors affecting the harmonization of disease-related metabolic brain pattern expression quantification in [(18)F]FDG-PET (PETMETPAT). Alzheimers Dement (Amst). 2019;11:472–82.
56.
van Veen R, Talavera Martinez L, Kogan RV, Meles SK, Mudali D, Roerdink JBTM, Massa F, Grazzini M, Obeso JA, Rodriguez-Oroz MC, Leenders KL, Renken RJ, de Vries JJG, Biehl M. Machine learning based analysis of FDG-PET image data for the diagnosis of neurodegenerative diseases. Application of Intelligent Systems (APPIS) 2018;in press.
57.
Mudali D, Teune LK, Renken RJ, Leenders KL, Roerdink JB. Classification of parkinsonian syndromes from FDG-PET brain data using decision trees with SSM/PCA features. Comput Math Methods Med. 2015;2015:136921.PubMedPubMedCentral
58.
Mudali D, Biehl M, Meles SK, Renken RJ, Garcia-Garcia D, Clavero P, et al. Differentiating early and late stage Parkinson’s disease from healthy controls. JBEMi. 2016;3(6):33–43.
59.
Manzanera OM, Meles SK, Leenders KL, Renken RJ, Pagani M, Arnaldi D, Nobili F, Obeso J, Oroz MR, Morbelli S, Maurits NM. Scaled Subprofile Modeling and Convolutional Neural Networks for the Identification of Parkinson’s Disease in 3D Nuclear Imaging Data. International Journal of Neural Systems. (2019);29(9).
Metadata
Title
Abnormal pattern of brain glucose metabolism in Parkinson’s disease: replication in three European cohorts
Authors
Sanne K. Meles
Remco J. Renken
Marco Pagani
L. K. Teune
Dario Arnaldi
Silvia Morbelli
Flavio Nobili
Teus van Laar
Jose A. Obeso
Maria C. Rodríguez-Oroz
Klaus L. Leenders
Publication date
01-02-2020
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 2/2020
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-019-04570-7

Other articles of this Issue 2/2020

European Journal of Nuclear Medicine and Molecular Imaging 2/2020 Go to the issue

Original Article

In vivo imaging of synaptic loss in Alzheimer’s disease with [18F]UCB-H positron emission tomography

Original Article

Cognitive signature of brain FDG PET based on deep learning: domain transfer from Alzheimer’s disease to Parkinson’s disease

Original Article

Functional impact of subthalamotomy by magnetic resonance–guided focused ultrasound in Parkinson’s disease: a hybrid PET/MR study of resting-state brain metabolism

Original Article

Characterization of the serotonin 2A receptor selective PET tracer (R)-[18F]MH.MZ in the human brain

Image of the Month

The tail of the striatum uncovered by FP-CIT PET in isolated striatocapsular infarct

Correction

Correction to: Glioblastoma multiforme: another potential application for 68Ga-PSMA PET/CT as a guide for targeted therapy